Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2004 Filed Apr 27, 2004 19:06 UTC |
OWEN DAVIDDirector
|
GrantOption (right to buy) · Derivative | 5,825 | $0.00 Strike: $41.20 | $0.00 |
DisclosureSEC source: 0001104659-04-011391 · a4.xml · derivative · entry 2 OWEN DAVID · CIK 0001239142 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,825 Underlying: common shares · 5,825 shares Expires 2014-04-22 F3 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b). It contains a replacement option feature. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:06 UTC |
OWEN DAVIDDirector
|
GrantCommon shares without par value | 1,577 | $41.20 | $64,972.40 |
DisclosureSEC source: 0001104659-04-011391 · a4.xml · nonDerivative · entry 1 OWEN DAVID · CIK 0001239142 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,133 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. F2 · balance_after: Includes shares acquired under the Abbott Laboratories Dividend Reinvestment and Stock Purchase Plan. These transactions are exempt from Section 16 under Rule 16a-11. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:07 UTC |
RAND A BARRYDirector
|
GrantOption (right to buy) · Derivative | 4,077 | $0.00 Strike: $41.20 | $0.00 |
DisclosureSEC source: 0001104659-04-011393 · a4.xml · derivative · entry 2 RAND A BARRY · CIK 0001012979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,077 Underlying: common shares · 4,077 shares Expires 2014-04-22 F3 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b). It contains a replacement option feature. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:07 UTC |
RAND A BARRYDirector
|
GrantCommon shares without par value | 1,577 | $41.20 | $64,972.40 |
DisclosureSEC source: 0001104659-04-011393 · a4.xml · nonDerivative · entry 1 RAND A BARRY · CIK 0001012979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,247 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. F2 · balance_after: Includes shares acquired under the Abbott Laboratories Dividend Reinvestment and Stock Purchase Plan. These transactions are exempt from Section 16 under Rule 16a-11. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:07 UTC |
REYNOLDS W ANNDirector
|
GrantOption (right to buy) · Derivative | 6,699 | $0.00 Strike: $41.20 | $0.00 |
DisclosureSEC source: 0001104659-04-011394 · a4.xml · derivative · entry 4 REYNOLDS W ANN · CIK 0001018652 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,699 Underlying: common shares · 6,699 shares Expires 2014-04-22 F4 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b). It contains a replacement option feature. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:07 UTC |
REYNOLDS W ANNDirector
|
GrantCommon shares without par value | 1,577 | $41.20 | $64,972.40 |
DisclosureSEC source: 0001104659-04-011394 · a4.xml · nonDerivative · entry 1 REYNOLDS W ANN · CIK 0001018652 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,986 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:08 UTC |
ROBERTS ROY SDirector
|
GrantOption (right to buy) · Derivative | 5,825 | $0.00 Strike: $41.20 | $0.00 |
DisclosureSEC source: 0001104659-04-011395 · a4.xml · derivative · entry 2 ROBERTS ROY S · CIK 0001200813 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,825 Underlying: common shares · 5,825 shares Expires 2014-04-22 F2 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b). It contains a replacement option feature. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:08 UTC |
ROBERTS ROY SDirector
|
GrantCommon shares without par value | 1,577 | $41.20 | $64,972.40 |
DisclosureSEC source: 0001104659-04-011395 · a4.xml · nonDerivative · entry 1 ROBERTS ROY S · CIK 0001200813 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,492 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:08 UTC |
SMITHBURG WILLIAM DDirector
|
Grantcommon shares without par value | 1,577 | $41.20 | $64,972.40 |
DisclosureSEC source: 0001104659-04-011396 · a4.xml · nonDerivative · entry 1 SMITHBURG WILLIAM D · CIK 0001190304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,007 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:09 UTC |
WALTER JOHN RDirector
|
GrantOption (right to buy) · Derivative | 5,825 | $0.00 Strike: $41.20 | $0.00 |
DisclosureSEC source: 0001104659-04-011397 · a4.xml · derivative · entry 4 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,825 Underlying: common shares · 5,825 shares Expires 2014-04-22 F4 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b). It contains a replacement option feature. Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:09 UTC |
WALTER JOHN RDirector
|
GrantCommon shares without par value | 1,577 | $41.20 | $64,972.40 |
DisclosureSEC source: 0001104659-04-011397 · a4.xml · nonDerivative · entry 1 WALTER JOHN R · CIK 0001046302 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,586 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 20, 2004 Filed Apr 22, 2004 19:35 UTC |
NEMMERS JOSEPH MSenior Vice President
|
GrantOption (right to buy) · Derivative | 13,684 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001104659-04-010939 · a4.xml · derivative · entry 9 NEMMERS JOSEPH M · CIK 0001264007 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,684 Underlying: common shares · 13,684 shares Expires 2013-02-13 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| April 20, 2004 Filed Apr 22, 2004 19:35 UTC |
NEMMERS JOSEPH MSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 15,569 | $0.00 Strike: $35.36 | $0.00 |
DisclosureSEC source: 0001104659-04-010939 · a4.xml · derivative · entry 8 NEMMERS JOSEPH M · CIK 0001264007 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,431 Underlying: common shares · 15,569 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| April 20, 2004 Filed Apr 22, 2004 19:35 UTC |
NEMMERS JOSEPH MSenior Vice President
|
Tax withholdingCommon shares without par value | 13,684 | $44.20 | $604,832.80 |
DisclosureSEC source: 0001104659-04-010939 · a4.xml · nonDerivative · entry 2 NEMMERS JOSEPH M · CIK 0001264007 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,456 Read SEC document |
| April 20, 2004 Filed Apr 22, 2004 19:35 UTC |
NEMMERS JOSEPH MSenior Vice President
|
Exercise / conversionCommon shares without par value | 15,569 | $35.36 | $550,519.84 |
DisclosureSEC source: 0001104659-04-010939 · a4.xml · nonDerivative · entry 1 NEMMERS JOSEPH M · CIK 0001264007 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2004 Filed Apr 20, 2004 19:00 UTC |
WASCOE THOMAS MSenior Vice President
|
GrantOption (right to buy) · Derivative | 16,685 | $0.00 Strike: $43.97 | $0.00 |
DisclosureSEC source: 0001104659-04-010603 · a4.xml · derivative · entry 6 WASCOE THOMAS M · CIK 0001239130 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,685 Underlying: common shares · 16,685 shares Expires 2010-02-10 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| April 16, 2004 Filed Apr 20, 2004 19:00 UTC |
WASCOE THOMAS MSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 6,386 | $0.00 Strike: $34.70 | $0.00 |
DisclosureSEC source: 0001104659-04-010603 · a4.xml · derivative · entry 5 WASCOE THOMAS M · CIK 0001239130 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,614 Underlying: common shares · 6,386 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| April 16, 2004 Filed Apr 20, 2004 19:00 UTC |
WASCOE THOMAS MSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 12,741 | $0.00 Strike: $34.70 | $0.00 |
DisclosureSEC source: 0001104659-04-010603 · a4.xml · derivative · entry 4 WASCOE THOMAS M · CIK 0001239130 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: common shares · 12,741 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| April 16, 2004 Filed Apr 20, 2004 19:00 UTC |
WASCOE THOMAS MSenior Vice President
|
Tax withholdingCommon shares without par value | 16,685 | $43.97 | $733,639.45 |
DisclosureSEC source: 0001104659-04-010603 · a4.xml · nonDerivative · entry 2 WASCOE THOMAS M · CIK 0001239130 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,991 Read SEC document |
| April 16, 2004 Filed Apr 20, 2004 19:00 UTC |
WASCOE THOMAS MSenior Vice President
|
Exercise / conversionCommon shares without par value | 19,127 | $34.70 | $663,706.90 |
DisclosureSEC source: 0001104659-04-010603 · a4.xml · nonDerivative · entry 1 WASCOE THOMAS M · CIK 0001239130 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2004 Filed Apr 1, 2004 23:07 UTC |
SMITHBURG WILLIAM DDirector
|
GrantStock equivalent units · Derivative | 558 | $41.16 Strike: $0.00 | $22,967.28 |
DisclosureSEC source: 0001104659-04-009236 · a4.xml · derivative · entry 1 SMITHBURG WILLIAM D · CIK 0001190304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,081 Underlying: common shares · 558 shares Expires not disclosed F1 · derivative.exercise_price: Director fees deferred and credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees deferred and credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees deferred and credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2004 Filed Apr 1, 2004 23:09 UTC |
POWELL BOONE JRDirector
|
GrantStock equivalent units · Derivative | 303 | $41.16 Strike: $0.00 | $12,471.48 |
DisclosureSEC source: 0001104659-04-009237 · a4.xml · derivative · entry 1 POWELL BOONE JR · CIK 0001232973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,348 Underlying: common shares · 303 shares Expires not disclosed F1 · derivative.exercise_price: Director fees deferred and credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees deferred and credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees deferred and credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2004 Filed Apr 2, 2004 15:33 UTC |
LIEPMANN HOLGER ASenior Vice President
|
GrantOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $41.10 | $0.00 |
DisclosureSEC source: 0001104659-04-009263 · a4.xml · derivative · entry 5 LIEPMANN HOLGER A · CIK 0001283517 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: common shares · 25,000 shares Expires 2014-03-30 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 8,334 on 3/31/05, 8,333 on 3/31/06 and 8,333 on 3/31/07. Read SEC document |
| March 31, 2004 Filed Apr 2, 2004 15:33 UTC |
LIEPMANN HOLGER ASenior Vice President
|
GrantCommon shares without par value | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-04-009263 · a4.xml · nonDerivative · entry 1 LIEPMANN HOLGER A · CIK 0001283517 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,912 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:13 UTC |
ASHLEY RICHARD WExecutive Vice President
|
GrantCommon shares without par value | 28,000 | $43.66 | $1,222,480.00 |
DisclosureSEC source: 0001104659-04-005598 · a4.xml · nonDerivative · entry 1 ASHLEY RICHARD W · CIK 0001278570 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16b under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:14 UTC |
GONZALEZ RICHARD ADirector · President and COO
|
GrantOption (right to buy) · Derivative | 270,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005599 · a4.xml · derivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: common shares · 270,000 shares Expires 2014-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 1/3, 1/3, and 1/3 beginning on February 20, 2005, the first anniversary date of the grant. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:14 UTC |
GONZALEZ RICHARD ADirector · President and COO
|
GrantCommon shares without par value | 40,000 | $43.66 | $1,746,400.00 |
DisclosureSEC source: 0001104659-04-005599 · a4.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,688 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:14 UTC |
BEGLEY CHRISTOPHER BSenior Vice President
|
GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005600 · a4.xml · derivative · entry 3 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: common shares · 55,000 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16b under Rule 16b-3. The option becomes exercisable in annual increments of 18,334 on 2/20/05, 18,333 on 2/20/06 and 18,333 on 2/20/07. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:14 UTC |
BEGLEY CHRISTOPHER BSenior Vice President
|
GrantCommon shares without par value | 8,000 | $43.66 | $349,280.00 |
DisclosureSEC source: 0001104659-04-005600 · a4.xml · nonDerivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,124 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16b under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:14 UTC |
MCCULLOUGH GARY ESenior Vice President
|
GrantOption (right to buy · Derivative | 55,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005601 · a4.xml · derivative · entry 2 MCCULLOUGH GARY E · CIK 0001163212 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: common shares · 55,000 shares Expires 2014-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 18,334 on 2/20/05, 18,333 on 2/20/06 and 18,333 on 2/20/07. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:14 UTC |
MCCULLOUGH GARY ESenior Vice President
|
GrantCommon shares without par value | 8,000 | $43.66 | $349,280.00 |
DisclosureSEC source: 0001104659-04-005601 · a4.xml · nonDerivative · entry 1 MCCULLOUGH GARY E · CIK 0001163212 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:14 UTC |
DE LASA JOSE MExecutive Vice President
|
GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005602 · a4.xml · derivative · entry 3 DE LASA JOSE M · CIK 0001239418 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: common shares · 55,000 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16b under Rule 16b-3. The option becomes exercisable in annual increments of 18,334 on 2/20/05, 18,333 on 2/20/06 and 18,333 on 2/20/07. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:14 UTC |
DE LASA JOSE MExecutive Vice President
|
GrantCommon shares without par value | 8,000 | $43.66 | $349,280.00 |
DisclosureSEC source: 0001104659-04-005602 · a4.xml · nonDerivative · entry 1 DE LASA JOSE M · CIK 0001239418 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,929 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16b under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:14 UTC |
LINDER GREG WVice President
|
GrantOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005603 · a4.xml · derivative · entry 3 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: common shares · 25,000 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 8,334 on 2/20/05, 8,333 on 2/20/06 and 8,333 on 2/20/07. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:14 UTC |
LINDER GREG WVice President
|
GrantCommon shares without par value | 3,500 | $43.66 | $152,810.00 |
DisclosureSEC source: 0001104659-04-005603 · a4.xml · nonDerivative · entry 1 LINDER GREG W · CIK 0001239128 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,497 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:15 UTC |
HERRERA GUILLERMO ASenior Vice President
|
GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005604 · a4.xml · derivative · entry 3 HERRERA GUILLERMO A · CIK 0001242826 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: common shares · 55,000 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 18,334 on 2/20/05, 18,333 on 2/20/06 and 18,333 on 2/20/07. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:15 UTC |
HERRERA GUILLERMO ASenior Vice President
|
GrantCommon shares without par value | 8,000 | $43.66 | $349,280.00 |
DisclosureSEC source: 0001104659-04-005604 · a4.xml · nonDerivative · entry 1 HERRERA GUILLERMO A · CIK 0001242826 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,979 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:15 UTC |
DEMPSEY WILLIAM GSenior Vice President
|
GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005605 · a4.xml · derivative · entry 3 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: common shares · 55,000 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 18,334 on 2/20/05, 18,333 on 2/20/06 and 18,333 on 2/20/07. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:15 UTC |
DEMPSEY WILLIAM GSenior Vice President
|
GrantCommon shares without par value | 8,000 | $43.66 | $349,280.00 |
DisclosureSEC source: 0001104659-04-005605 · a4.xml · nonDerivative · entry 1 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,916 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:15 UTC |
FREYMAN THOMAS CExecutive Vice President
|
GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005607 · a4.xml · derivative · entry 3 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: common shares · 55,000 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 18,334 on 2/20/05, 18,333 on 2/20/06 and 18,333 on 2/20/07. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:15 UTC |
FREYMAN THOMAS CExecutive Vice President
|
GrantCommon shares without par value | 8,000 | $43.66 | $349,280.00 |
DisclosureSEC source: 0001104659-04-005607 · a4.xml · nonDerivative · entry 1 FREYMAN THOMAS C · CIK 0001239126 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,237 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:15 UTC |
WASCOE THOMAS MSenior Vice President
|
GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005606 · a4.xml · derivative · entry 3 WASCOE THOMAS M · CIK 0001239130 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: common shares · 55,000 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 18,334 on 2/20/05, 18,333 on 2/20/06 and 18,333 on 2/20/07. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:15 UTC |
WASCOE THOMAS MSenior Vice President
|
GrantCommon shares without par value | 8,000 | $43.66 | $349,280.00 |
DisclosureSEC source: 0001104659-04-005606 · a4.xml · nonDerivative · entry 1 WASCOE THOMAS M · CIK 0001239130 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,549 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:16 UTC |
WHITE MILES DDirector · Chairman, CEO
|
GrantOption (right to buy) · Derivative | 380,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005608 · a4.xml · derivative · entry 6 WHITE MILES D · CIK 0001239129 · Director · Chairman, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,000 Underlying: common shares · 380,000 shares Expires 2014-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 126,667 on 2/20/05, 126,666 on 2/20/06 and 126,667 on 2/20/07 Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:16 UTC |
WHITE MILES DDirector · Chairman, CEO
|
GrantCommon shares without par value | 55,000 | $43.66 | $2,401,300.00 |
DisclosureSEC source: 0001104659-04-005608 · a4.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · Chairman, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,685 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:16 UTC |
LEIDEN JEFFREY MDirector · President and COO
|
GrantOption (right to buy) · Derivative | 270,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005609 · a4.xml · derivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: common shares · 270,000 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16b under Rule 16b-3. The option becomes exercisable in annual increments of 1/3, 1/3, and 1/3 beginning on February 20, 2005, the first anniversary date of the grant. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:16 UTC |
LEIDEN JEFFREY MDirector · President and COO
|
GrantCommon shares without par value | 40,000 | $43.66 | $1,746,400.00 |
DisclosureSEC source: 0001104659-04-005609 · a4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,992 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16b under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:16 UTC |
WYATT LANCE BSenior Vice President
|
GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005610 · a4.xml · derivative · entry 3 WYATT LANCE B · CIK 0001239421 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: common shares · 55,000 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 18,334 on 2/20/05, 18,333 on 2/20/06 and 18,333 on 2/20/07. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:16 UTC |
WYATT LANCE BSenior Vice President
|
GrantCommon shares without par value | 8,000 | $43.66 | $349,280.00 |
DisclosureSEC source: 0001104659-04-005610 · a4.xml · nonDerivative · entry 1 WYATT LANCE B · CIK 0001239421 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,527 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:25 UTC |
NEMMERS JOSEPH MSenior Vice President
|
GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005613 · a4.xml · derivative · entry 7 NEMMERS JOSEPH M · CIK 0001264007 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: common shares · 55,000 shares Expires 2014-02-19 F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 18,334 on 2/20/05, 18,333 on 2/20/06 and 18,333 on 2/20/07. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.